Using Statins To Lower Cholesterol May Be More Beneficial Way To Prevent Heart Attack And Stroke

Using Statins To Lower Cholesterol May Be More Beneficial Way To Prevent Heart Attack And Stroke.
Broader use of cholesterol-lowering statins may be a cost-effective sense to halt humanitarianism attack and stroke, US researchers suggest. In the study, published online Sept 27, 2010 in the periodical Circulation neosize xl modo. The researchers also found that screening for excited sensitivity C-reactive protein (CRP) to identify patients who may benefit from statin group therapy is only cost-effective in certain cases.

Elevated levels of CRP indicate inflammation and suggest an increased chance for heart attack and stroke remove. Currently, statin therapy is recommended for high-risk patients - those with a 20 percent or greater hazard of some type of cardiovascular event within the next 10 years.

But statins may also better people with a lower risk, according to Dr Mark Hlatky, professor of health analysis and policy and of cardiovascular medicine at Stanford University School of Medicine in Stanford, Calif, and colleagues. Hlatky's yoke set out to determine the cost-effectiveness of three statin therapy approaches in patients with customary cholesterol levels and no evidence of heart disease or diabetes: following current guidelines; conducting CRP screening in patients who don't contest current statin treatment guidelines and offering statins to those with lifted CRP levels; and providing statin therapy based on a patient's cardiovascular jeopardy alone, with no CRP testing.

The researchers analyzed which of the three approaches met the generally accepted cost-effectiveness dawn of no more than $50000 per quality-adjusted life-year. They found that statin therapy based on cardiovascular jeopardize alone, without CRP testing, was the most cost-effective strategy.

Initiating statin treatment at lower danger levels - without CRP testing - "would further improve clinical outcomes at adequate cost, making it the optimally cost-effective strategy in our analysis," the researchers wrote in a university story release. "Ideally, a marker would tell us who will benefit from drug treatment and who will not," Hlatky keen out in the release. "If a test could give us that information, it would be very cost-effective reloramax. But there's not good evidence yet that CRP, or any other test, workshop that well".